Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Percutaneous Endocardial Septal Radiofrequency Ablation in the Treatment of Obstructive Hypertrophic Cardiomyopathy: a Prospective, Multicenter, Single-arm Objective Performance Criteria Trial

NCT06224621 is registered in ClinicalTrials.gov with China National Center for Cardiovascular Diseases as lead sponsor.

NCT NCT06224621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06224621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Percutaneous Endocardial Septal Radiofrequency Ablation in the Treatment of Obstructive Hypertrophic Cardiomyopathy: a Prospective, Multicenter, Single-arm Objective Performance Criteria Trial
Lead sponsor
China National Center for Cardiovascular Diseases
Phase
Not applicable
Overall status
Unknown status
Start date
January 31, 2024
Completion date
January 31, 2026
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obstructive hypertrophic cardiomyopathy